A review of activity indices and efficacy Endpoints for clinical trials of medical therapy in adults with Crohn's disease

被引：584

作者：

Sandborn, WJ

Feagan, BG

Hanauer, SB

Lochs, H

Löfberg, R

Modigliani, R

Present, DH

Rutgeerts, P

Schölmerich, J

Stange, EF

Sutherland, LR

机构：

[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA

[2] Univ Western Ontario, London, ON, Canada

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Berlin, Klinikum Charite, Schwerpunkt Gastroenterol Hepatol & Endokrinol, Berlin, Germany

[5] Huddinge Univ Hosp, S-14186 Huddinge, Sweden

[6] Hop St Louis, Paris, France

[7] CUNY Mt Sinai Sch Med, New York, NY 10029 USA

[8] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[9] Univ Regensburg, D-8400 Regensburg, Germany

[10] Robert Bosch Krankenhaus, Stuttgart, Germany

[11] Dept Community Hlth Sci, Calgary, AB, Canada

来源：

GASTROENTEROLOGY | 2002年 / 122卷 / 02期

关键词：

D O I：

10.1053/gast.2002.31072

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：512 / 530

页数：19

共 115 条

[101]

Steinhart AH, 1998, INFLAMM BOWEL DIS, V4, P228

[102]

SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847

[103] DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF METRONIDAZOLE IN CROHNS-DISEASE [J].

SUTHERLAND, L ;

SINGLETON, J ;

SESSIONS, J ;

HANAUER, S ;

KRAWITT, E ;

RANKIN, G ;

SUMMERS, R ;

MEKHJIAN, H ;

GREENBERGER, N ;

KELLY, M ;

LEVINE, J ;

THOMSON, A ;

ALPERT, E ;

PROKIPCHUK, E .

GUT, 1991, 32 (09) :1071-1075

[104] A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease [J].

Sutherland, LR ;

Martin, F ;

Bailey, RJ ;

Fedorak, RN ;

Poleski, M ;

Dallaire, C ;

Rossman, R ;

Saibil, F ;

Lariviere, L ;

Meyer, D ;

Baker, SJ ;

Alvi, AW ;

Bass, S ;

Blustein, PK ;

Bridges, RJ ;

Lay, TE ;

vanRosendaal, GMA ;

Watson, MH ;

Clermont, R ;

Cockeram, AW ;

Mabey, M ;

DaCosta, L ;

Beck, IT ;

Depew, W ;

Groll, A ;

Paterson, W ;

Simon, J ;

Vanner, S ;

DAmore, D ;

Sherbaniuk, R ;

Cherry, R ;

Lalor, E ;

Thomson, ABR ;

Yacyshyn, B ;

Bain, V ;

Fisher, D ;

Kirdeikis, P ;

Halle, P ;

Irvine, EJ ;

Collins, SM ;

Croitoru, K ;

Crowe, SE ;

Goodacre, RL ;

Hunt, RH ;

Sabena, BJ ;

Donnelly, M ;

Khan, MAR ;

Langevin, S ;

Menard, DB ;

Haddad, H .

GASTROENTEROLOGY, 1997, 112 (04) :1069-1077

[105]

TALAL AH, 1995, GASTROENTEROL CLIN N, V24, P699

[106] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease [J].

Targan, SR ;

Hanauer, SB ;

vanDeventer, SJH ;

Mayer, L ;

Present, DH ;

Braakman, T ;

DeWoody, KL ;

Schaible, TF ;

Rutgeerts, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) :1029-1035

[107] A comparison of budesonide and mesalamine for active Crohn's disease [J].

Thomsen, OO ;

Cortot, A ;

Jewell, D ;

Wright, JP ;

Winter, T ;

Veloso, FT ;

Vatn, M ;

Persson, T ;

Pettersson, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) :370-374

[108]

Thomson ABR, 1995, ALIMENT PHARM THERAP, V9, P673

[109] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE ORAL MESALAMINE (5-ASA) PREPARATION, ASACOL, IN THE TREATMENT OF SYMPTOMATIC CROHNS COLITIS AND ILEOCOLITIS [J].

TREMAINE, WJ ;

SCHROEDER, KW ;

HARRISON, JM ;

ZINSMEISTER, AR .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 1994, 19 (04) :278-282

[110] AN INDEX OF INFLAMMATORY ACTIVITY IN PATIENTS WITH CROHNS-DISEASE [J].

VANHEES, PAM ;

VANELTEREN, PH ;

VANLIER, HJJ ;

VANTONGEREN, JHM .

GUT, 1980, 21 (04) :279-286

← 3 4 5 6 7 8 9 10 11 12 →